On Tuesday, Amicus Therapeutics Inc (NASDAQ: FOLD) opened lower -5.29% from the last session, before settling in for the closing price of $6.24. Price fluctuations for FOLD have ranged from $5.51 to $12.65 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 34.10%. Company’s average yearly earnings per share was noted 51.94% at the time writing. With a float of $297.12 million, this company’s outstanding shares have now reached $307.92 million.
Considering the fact that the conglomerate employs 499 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 90.99%, operating margin of 7.11%, and the pretax margin is -0.59%.
Amicus Therapeutics Inc (FOLD) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Amicus Therapeutics Inc is 3.51%, while institutional ownership is 100.77%. The most recent insider transaction that took place on Feb 19 ’25, was worth 4,000. In this transaction President and CEO of this company sold 400 shares at a rate of $10.00, taking the stock ownership to the 1,150,657 shares. Before that another transaction happened on Feb 19 ’25, when Company’s Director proposed sale 400 for $9.85, making the entire transaction worth $3,940.
Amicus Therapeutics Inc (FOLD) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 51.94% per share during the next fiscal year.
Amicus Therapeutics Inc (NASDAQ: FOLD) Trading Performance Indicators
Check out the current performance indicators for Amicus Therapeutics Inc (FOLD). In the past quarter, the stock posted a quick ratio of 2.47. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.35. Likewise, its price to free cash flow for the trailing twelve months is 1130.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.09, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach 0.26 in one year’s time.
Technical Analysis of Amicus Therapeutics Inc (FOLD)
Compared to the last year’s volume of 3.79 million, its volume of 3.53 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 49.40%.
During the past 100 days, Amicus Therapeutics Inc’s (FOLD) raw stochastic average was set at 9.69%, which indicates a significant decrease from 42.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.23 in the past 14 days, which was lower than the 0.28 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.09, while its 200-day Moving Average is $8.62. Nevertheless, the first resistance level for the watch stands at $6.19 in the near term. At $6.46, the stock is likely to face the second major resistance level. The third major resistance level sits at $6.62. If the price goes on to break the first support level at $5.76, it is likely to go to the next support level at $5.60. Should the price break the second support level, the third support level stands at $5.33.
Amicus Therapeutics Inc (NASDAQ: FOLD) Key Stats
There are currently 307,931K shares outstanding in the company with a market cap of 1.82 billion. Presently, the company’s annual sales total 528,300 K according to its annual income of -56,110 K. Last quarter, the company’s sales amounted to 125,250 K and its income totaled -21,690 K.
